Platelet‐Derived S100A8/A9 and Cardiovascular Disease in Systemic Lupus Erythematosus

Levels of S100A8/A9, a proinflammatory and prothrombotic protein complex, are increased in several diseases, and high levels predispose to cardiovascular disease (CVD). Recently, platelet S100A8/A9 synthesis was described in mice and humans in relation to CVD. The aim of this study was to investigate the role of platelet S100A8/A9 in systemic lupus erythematosus (SLE), a disease with markedly increased cardiovascular morbidity, as well as the exact platelet distribution of the S100A8/A9 proteins.

[1]  L. Truedsson,et al.  Platelet Activation and Anti-Phospholipid Antibodies Collaborate in the Activation of the Complement System on Platelets in Systemic Lupus Erythematosus , 2014, PloS one.

[2]  A. Schmaier,et al.  Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. , 2014, The Journal of clinical investigation.

[3]  S. Pettersson,et al.  Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus , 2014, Annals of the rheumatic diseases.

[4]  L. Truedsson,et al.  Pathogenic Mechanisms in Lupus Nephritis: Nucleosomes Bind Aberrant Laminin β1 With High Affinity and Colocalize in the Electron‐Dense Deposits , 2014, Arthritis & rheumatology.

[5]  B. Hedblad,et al.  Plasma S100A8/A9 Correlates With Blood Neutrophil Counts, Traditional Risk Factors, and Cardiovascular Disease in Middle-Aged Healthy Individuals , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[6]  O. Nived,et al.  Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. , 2013, Rheumatology.

[7]  L. Truedsson,et al.  Increased serum type I interferon activity in early systemic sclerosis patients is associated with antibodies against Sjögren’s syndrome antigens and nuclear ribonucleoprotein antigens , 2013, Scandinavian journal of rheumatology.

[8]  Elena Aikawa,et al.  Macrophage-Derived Matrix Vesicles: An Alternative Novel Mechanism for Microcalcification in Atherosclerotic Plaques , 2013, Circulation research.

[9]  L. Morozova-Roche,et al.  Aggregation of Human S100A8 and S100A9 Amyloidogenic Proteins Perturbs Proteostasis in a Yeast Model , 2013, PloS one.

[10]  K. Ahuja,et al.  Anti-&bgr;2GP1 antibodies have variable effects on platelet aggregation , 2013, Pathology.

[11]  A. Helenius,et al.  Investigating Endocytic Pathways to the Endoplasmic Reticulum and to the Cytosol Using SNAP‐Trap , 2013, Traffic.

[12]  M. Seaman.  The retromer complex – endosomal protein recycling and beyond , 2012, Journal of Cell Science.

[13]  G. Sturfelt,et al.  Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus – a possible link to venous thrombosis? , 2012, Lupus.

[14]  L. Rönnblom,et al.  Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[15]  A. Blom,et al.  Neutrophil Extracellular Traps That Are Not Degraded in Systemic Lupus Erythematosus Activate Complement Exacerbating the Disease , 2012, The Journal of Immunology.

[16]  O. Nived,et al.  Cardiovascular event in systemic lupus erythematosus in northern Sweden: Incidence and predictors in a 7-year follow-up study , 2012, Lupus.

[17]  P. Gleeson,et al.  The Regulation of Endosome‐to‐Golgi Retrograde Transport by Tethers and Scaffolds , 2011, Traffic.

[18]  L. Truedsson,et al.  Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus , 2011, Arthritis research & therapy.

[19]  L. Truedsson,et al.  Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. , 2010, Blood.

[20]  J. Moreau,et al.  Platelet CD154 Potentiates Interferon-α Secretion by Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus , 2010, Science Translational Medicine.

[21]  A. Sato,et al.  Enhanced expression of the S100A8/A9 complex in acute myocardial infarction patients. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[22]  L. Hansson,et al.  Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study , 2009, Arthritis research & therapy.

[23]  F. Moll,et al.  Abstract 5171: High Levels of Myeloid-related Protein 14 in Human Atherosclerotic Plaques Correlate With the Characteristics of Rupture-prone Lesions , 2009, Circulation.

[24]  T. Vogl,et al.  Phagocyte-specific S100A8/A9 Protein Levels During Disease Exacerbations and Infections in Systemic Lupus Erythematosus , 2009, The Journal of Rheumatology.

[25]  A. Syvänen,et al.  A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus , 2009, Annals of the rheumatic diseases.

[26]  P. Libby,et al.  Myeloid-Related Protein-8/14 Is Critical for the Biological Response to Vascular Injury , 2009, Circulation.

[27]  T. Leanderson,et al.  Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides , 2009, PLoS biology.

[28]  K. Walley,et al.  S100A8 and S100A9 Mediate Endotoxin-Induced Cardiomyocyte Dysfunction via the Receptor for Advanced Glycation End Products , 2008, Circulation research.

[29]  R. Ramasamy,et al.  Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. , 2008, The Journal of clinical investigation.

[30]  W. Nacken,et al.  Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock , 2007, Nature Medicine.

[31]  P. Emery,et al.  The validity of the inclusion of "lupus headache" in the Systemic Lupus Erythematosus Disease Activity Index. , 2007, Arthritis and rheumatism.

[32]  M. Hersberger,et al.  Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. , 2007, European heart journal.

[33]  Stephen R. Clark,et al.  Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood , 2007, Nature Medicine.

[34]  P. Libby,et al.  Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Events , 2006, Circulation.

[35]  W. Chazin,et al.  The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis , 2006, Arthritis research & therapy.

[36]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[37]  D. Foell,et al.  Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. , 2005, Blood.

[38]  I. Thorey,et al.  MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. , 2004, Blood.

[39]  S. Pierangeli,et al.  Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. , 2004, Arthritis and rheumatism.

[40]  D. Gladman,et al.  Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.

[41]  M. Abrahamowicz,et al.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. , 2001, Arthritis and rheumatism.

[42]  W. Nacken,et al.  Interaction of S100A8/S100A9-arachidonic acid complexes with the scavenger receptor CD36 may facilitate fatty acid uptake by endothelial cells. , 2001, Biochemistry.

[43]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[44]  M. Hartmann,et al.  Myeloid-related Protein (MRP) 8 and MRP14, Calcium-binding Proteins of the S100 Family, Are Secreted by Activated Monocytes via a Novel, Tubulin-dependent Pathway* , 1997, The Journal of Biological Chemistry.

[45]  R. D'Agostino,et al.  Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. , 1997, American journal of epidemiology.

[46]  D. Symmons,et al.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[47]  G. Hughes,et al.  Calprotectin in Patients with Systemic Lupus Erythematosus: Relation to Clinical and Laboratory Parameters of Disease Activity , 1993, Lupus.

[48]  W. Baschong,et al.  Small colloidal gold conjugated to Fab fragments or to immunoglobulin G as high-resolution labels for electron microscopy: a technical overview. , 1990, Journal of electron microscopy technique.

[49]  M. Sakaguchi,et al.  S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis. , 2013, Cancer research.

[50]  Cardiovascular Diabetology BioMed Central Original investigation , 2007 .

[51]  Orphanet Journal of Rare Diseases BioMed Central Review , 2006 .